Pharma Licensing & Regulatory Compliance PK

Executive Overview & Strategic Scope

The establishment, licensing, and ongoing regulatory compliance of pharmaceutical manufacturing units, import-export houses, and distribution networks in Pakistan demand rigorous adherence to federal and provincial health statutes. Operated under the stringent oversight of the Drug Regulatory Authority of Pakistan (DRAP), the Drug Act 1976, and associated Good Manufacturing Practices (GMP), pharmaceutical enterprises face complex legal prerequisites. Javid Law Associates provides high-level corporate and regulatory advocacy, ensuring that commercial entities successfully navigate licensing protocols, facility inspections, Drug Registration Board (DRB) approvals, and statutory corporate filings through SECP eZfile and FBR Iris 2.0. Our practice protects investors from procedural bottlenecks, administrative delays, and operational suspensions, securing lawful market entry and sustainable compliance.

Statutory & Regulatory Framework

Pharmaceutical operations in Pakistan are governed by a multi-tiered legislative framework. The primary statutes include the Drugs Act 1976, the Drug Regulatory Authority of Pakistan Act 2012, and the DRAP (Licensing, Manufacturing and Sale of Drugs) Rules 2007. Corporate structuring requires compliance with the Companies Act 2017 via SECP eZfile. Tax and fiscal compliance are regulated under the Income Tax Ordinance 2001 and Sales Tax Act 1990, alongside provincial revenue authorities (PRA, SRB, KPRA) for service levies. Intellectual property protection, including trademark registration of brand names, is governed by the Trademarks Ordinance 2001. Regulatory clearances must also be coordinated with federal and provincial environmental protection agencies (EPA) and municipal health authorities.

Statutory Deadlines, Penalties & Compliance Exposure

Non-compliance with pharmaceutical licensing and statutory reporting exposes promoters to severe legal liabilities under DRAP regulations and tax statutes. Operating without a valid establishment license or manufacturing unauthorized formulations attracts criminal prosecution, immediate facility sealing, and heavy penalties under Section 27 of the Drugs Act 1976. Corporate filing defaults under the Companies Act 2017 result in compounding fees and administrative blacklisting by SECP. Tax non-compliance triggers show-cause notices under Section 122/177 of the Income Tax Ordinance 2001, imposition of default surcharges u/s 205, sales tax audits u/s 25 of the Sales Tax Act 1990, and potential bank account attachment u/s 140.

Procedural Roadmap & Execution Phases

Chronological, step-by-step breakdown tailored specifically to Pharma Licensing & Regulatory Compliance PK:

• Phase 1: Corporate Incorporation & Statutory Due Diligence: Vetting client records, establishing the corporate entity via SECP eZfile, securing NTN/STRN via FBR Iris 2.0, and confirming site suitability.
• Phase 2: Architectural Blueprints & Technical Dossier Preparation: Drafting facility layouts, quality control laboratory specifications, HVAC validation reports, and technical dossiers for DRAP submission.
• Phase 3: DRAP Portal Lodgment & Official Application Filing: Formal submission of Form 1 / licensing applications to the Drug Regulatory Authority of Pakistan with required official fee challans.
• Phase 4: Inspection Defense, Panel Hearings & Deficiency Responses: Representing the client before DRAP Central Licensing Board (CLB) inspection panels, answering audit queries, and resolving technical observations.
• Phase 5: License Issuance, Product Registration & Post-Compliance Retainer: Procurement of the official manufacturing/import license, processing product registrations (DRB), and establishing ongoing corporate and tax compliance frameworks.

Why Choose Javid Law Associates

Javid Law Associates combines deep corporate and tax expertise with specialized regulatory advocacy across Pakistan. Headquartered in F-10 Markaz, Islamabad, our firm represents clients before the Drug Regulatory Authority of Pakistan (DRAP), Appellate Tribunals, and High Courts nationwide. Led by seasoned High Court advocates, we offer rigorous legal structuring, meticulous compliance auditing, and aggressive litigation support for pharmaceutical enterprises, ensuring absolute adherence to federal statutes while safeguarding commercial interests.